Ticagrelor is a known orally active compounds act as P2Y12 (formerly known as P2T receptor) receptor antagonists [1] and they are indicated for use in therapy as inhibitors of platelet activation, aggregation and degranulation, promoters of platelet disaggregation, and anti-thrombotic agents [2]. The present work describes a novel process of Ticagrelor and its novel intermediate synthesis, characterization and control of related substances, thereby providing a commercial method to synthesize substantially pure Ticagrelor.